Xenetic Biosciences, Inc.
XBIO
$2.30
-$0.08-3.36%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -1.57% | 7.15% | 16.79% | 27.09% | 48.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.57% | 7.15% | 16.79% | 27.09% | 48.80% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -1.57% | 7.15% | 16.79% | 27.09% | 48.80% |
| SG&A Expenses | -4.06% | 5.67% | 1.73% | -5.51% | -2.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.97% | -4.10% | 12.66% | -7.85% | -16.25% |
| Operating Income | 6.90% | 9.59% | -10.69% | 19.03% | 32.78% |
| Income Before Tax | 4.22% | 8.29% | -11.97% | 23.08% | 36.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.22% | 8.29% | -11.97% | 23.08% | 36.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.22% | 8.29% | -11.97% | 23.08% | 36.90% |
| EBIT | 6.90% | 9.59% | -10.69% | 19.03% | 32.78% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 4.98% | 9.56% | -9.03% | 27.31% | 41.61% |
| Normalized Basic EPS | 4.98% | 9.56% | -9.03% | 27.31% | 41.61% |
| EPS Diluted | 4.89% | 9.58% | -8.98% | 27.36% | 41.64% |
| Normalized Diluted EPS | 4.98% | 9.56% | -9.03% | 27.31% | 41.61% |
| Average Basic Shares Outstanding | 0.86% | 1.34% | 2.90% | 4.69% | 7.45% |
| Average Diluted Shares Outstanding | 0.86% | 1.34% | 2.90% | 4.69% | 7.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
